AVEO slides as Astellas shuns tivozanib in kidney cancer

AVEO Pharmaceuticals fell 12.6 after the market closed on 23 May to $2.27 per share following the company's disclosure that Astellas will not submit a marketing authorization application MAA in the EU…

---

Roche wins new targeted OK for Tarceva in EGFR-positive lung cancer

Along with its partner, Astellas, Roche has won FDA approval for a new, first-line use for its lung cancer drug Tarceva in patients whose cancers test positive for specific mutations of the EGFR gene.

---

AstraZeneca, Astellas among Optimer bidders, Bloomberg sources say

Who wants Optimer Pharmaceuticals and its high-powered antibiotics? A handful of drugmakers, apparently.

---

Astellas and Drais Partner to Develop Third Astellas Compound Through Tacurion

InterWest Partners, Sutter Hill Ventures and Astellas Venture Management Invest $15 Million Into Tacurion to Advance Compound…

---